Gilead Sciences (GILD) Cash & Current Investments (2009 - 2026)

Gilead Sciences (GILD) has reported Cash & Current Investments for 18 consecutive years, with $3.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments fell 39.02% year-over-year to $3.2 billion; the trailing twelve-month figure through Jun 2026 stood at $3.2 billion (down 39.02% YoY), and the FY2025 full-year result was $7.6 billion, down 23.61% from the prior year.
• Cash & Current Investments eased to $3.2 billion in Q2 2026 per GILD's latest filing, from $7.6 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $10.0 billion in Q4 2024 and bottomed at $2.8 billion in Q2 2024.
• Historically, Cash & Current Investments has averaged $6.2 billion across 5 years, with a median of $6.1 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments plunged 58.42% in 2024, then soared 88.06% in 2025.
• Over 5 years, Cash & Current Investments stood at $6.4 billion in 2022, then grew by 13.77% to $7.3 billion in 2023, then surged by 37.54% to $10.0 billion in 2024, then dropped by 23.61% to $7.6 billion in 2025, then sank by 58.35% to $3.2 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $3.2 billion, $7.6 billion, and $7.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.